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ABSTRACT  By the  use of a rat  IgG  monoclonal  antibody  (mab), a mouse mab and  human 
serum containing  an  IgM  mab, all  of which  react with  isolated human  myelin-associated 
glycoprotein (MAG) on immunoblots and bind only to proteins with relative mobilities identical 
to  MAG  and  dMAG  on  immunoblots  of  homogenates  of  adult  human  spinal cord,  we 
demonstrated  the following:  in  homogenates of central  nervous system tissue from  human 
fetuses of gestational ages that antedate myelination,  the anti-MAG antibodies react only with 
proteins  with  molecular  weights  of  250,000  or  larger. During  myelination  the  molecular 
weights of proteins with which the anti-MAG antibodies react shift towards the lower molecular 
weights found in adult myelin. Amongst those central nervous system regions examined, the 
shift towards the low molecular weights occurred  earliest in the region that is first to become 
myelinated and latest in the one that is the last to myelinate. Once myelination  is completed, 
the antibodies  react only with proteins with relative mobilities  identical  to those of MAG and 
dMAG. These developmental  changes in molecular  weights of "MAG-related  proteins"  may 
prove useful as an index of chemical processes on the basis of which myelination  occurs. 
Myelin-associated glycoprotein (MAG) 1 is an acidic, concan- 
avalin A binding glycoprotein that has been shown to be a 
minor component of both central (1) and peripheral myelin 
(2). Immunohistochemically it has been demonstrated in the 
inner and outer mesaxons and the Schmidt-Lanterman inci- 
sure of peripheral myelin sheaths (3) and in the periaxonal 
region of central myelin sheaths. MAG has also been found 
in  the  cytoplasm of oligodendrocytes prior  to  and  during 
myelination (4).  However, after myelination has been com- 
pleted  MAG  is  no  longer  detectable  in  oligodendrocytes. 
Interest in MAG was recently sparked when it was demon- 
strated that a group of patients with IgM monoclonal gam- 
mopathy and  demyelinating neuropathy have their mono- 
clonal IgMs directed against MAG (5, 6), and that when these 
IgMs are injected into the peripheral nerves of cats they cause 
demyelination (7).  It is also of medical interest that in acute 
lesions of multiple sclerosis a decrease in immunohistochem- 
l Abbreviations used in this paper: CNS, central nervous system; mab, 
monoclonal antibody; MAG, myelin-associated glycoprotein; MBP, 
myelin basic protein; PNS, peripheral nervous system. 
ically detectable MAG reaches well beyond the area of de- 
myelination  (8).  Immunohistochemical staining  for  MAG 
therefore appears to  provide a  sensitive  marker of myelin 
damage in multiple sclerosis. 
MAG  isolated  from  the  central  nervous  system  (CNS) 
myelin of rats or humans has a molecular weight of ~ 100,000 
(9).  Peripheral  nervous system (PNS)  MAG  has  a  slightly 
greater molecular weight than does CNS MAG but peptide 
maps of PNS  and CNS  MAG are identical  (2).  In human 
myelin there is a  neutral  protease that breaks down  MAG 
into dMAG which has a  molecular weight of-90,000 (10). 
During myelination in the rat CNS it has been shown that 
the molecular weight of MAG is greater than it is in adult 
myelin but the difference is small (11-13). 
In this  paper we describe  a  developmental alteration  in 
molecular weights of human CNS proteins that reacts with 
antibodies to MAG. At early stages the antibodies react only 
with proteins with molecular weights over 250,000;  in adult 
myelin they react only with proteins with molecular weights 
of 100,000  and  90,000.  There are also intermediate forms 
that are present during  various stages of myelination.  The 
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the parts of the CNS that become myelinated earliest. 
MATERIALS AND  METHODS 
Monoclonal  Antibodies  to  &lAG:  In attempts to  obtain  mabs 
specific for membrane-bound nicotinic acetylcholine receptor, Lewis rats were 
immunized  with receptor isolated from the electric organ of Torpedo californica 
(14). Splenic lymphocytes  from immune rats were fused with P2/0-Ag  14 mouse 
cells using the method of Kthler and Milstein (15).  Hybridoma supernatants 
were  subsequently screened in an enzyme-linked immunosorbent assay (16) 
against a membrane preparation from the electric  organ that contained acetyl- 
chofine receptor and was later shown to  be  contaminated by myefin. The 
electric organ of Torpedo californica  is heavily innervated by myelinated  axons. 
The hybridomas  yielding  positive supernatants  were cloned by limiting  dilutions 
and then recloned several times. Certain clones secreted mabs that on immu- 
noblots of  the receptor containing membrane preparation failed to bind to any 
component of nicotinic acetylcholine receptor but did bind to a protein with 
higher molecular weight.  This protein was later shown to be a myelin protein. 
One of these mabs, an IgG termed BRICk7, was selected for this study. BRIC3~ 
binds to  isolated human MAG on immunoblots, and on  immunoblots of 
homogenates  from adult spinal cord BRICa~ binds only to proteins with relative 
mobilities identical to those of MAG and dMAG (Fig.  I).  BRIC~ does not 
bind to anything  on immunoblots  ofhomogenates  from liver, kidney, or striated 
muscle. The immunohistochemical distribution of the antigenic determinant 
with which BRIC3~  reacts is identical to that of  MAG as defined with polyclonal 
antisera (3, 4). 
A  mouse mab (HNK,, Becton-Dickinson, Mountain View,  CA) that was 
originally raised against human natural killer cells but has subsequently been 
shown to react with MAG (17,  18) was also used. As control mabs we used 
several rat IgG mabs against the nicotinic aeetylcholine receptor (generously 
provided by D. P. Richman, Department of  Neurology, University of  Chicago) 
and the mouse mabs anti-Leu 2a and anti-Leu 3a (Becton-Dickinson). 
Human Serum Containing IgM Against  MAC:  We also  used 
serum from a  patient (M) with IgM~, monoclonal gammopathy and demye- 
linariog neuropathy. IgM in  this serum binds to  isolated human MAG on 
immunoblots  and on immunoblots  of  homogenates  of  adult human spinal cord 
binds only to proteins with relative mobilities identical to those of MAG and 
dMAG (Fig.  1) (6). Antibodies from the serum of patient M do not bind to 
anything on  immunoblots of homogenates from  liver,  kidney,  or  striated 
muscle. As controls we used sera from two patients with IgM monoclonal 
gammopathy unaccompanied by neuropathy. 
Attempts to Demonstrate  Binding of BRIC37 and IgM from 
the Serum of Patient M to Gangliosides Isolated from Human 
Peripheral  Nerves and Human  CNS:  Oangliosides  were isolated 
from fresh human sciatic nerves and human brains obtained at autopsy using 
a previously described method (19). The ganghosides were then separated by 
thin-layer  chromatography  (TLC) using  aluminum-backed  TLC plates (Silicagel 
60:  Merck, Darmstadt, Federal Republic of Germany). The plates were first 
developed in chloroform-methanol-0.2% CaCI2 in H20 (55-45-10,  by volume), 
then dried and redeveloped, this rime in chloroform-methanol-0.2% KC1 in 
2.5 M NFLOH (50-40-10,  by volume). Subsequently the plates were dried and 
cut into  1-cm wide strips that were placed individually into test tubes. The 
demonstration of binding of antibodies to the gangliosides on the plates was 
performed in the same manner as is described for binding of antibodies to 
proteins on nitrocellulose strips (see under Electrophoresis and Immunoblot- 
ring).  The IgM from the serum of patient M  bound to a  ganglioside from 
peripheral nerve (Fig.  2); it did not bind to anything in the CNS-ganglioside 
preparation. This is in keeping with what Ilyas et al. (20) have recently described 
using  sera from three patients with paraproteinemia and peripheral neuropathy. 
BRIC37 did neither bind to the peripheral nerve gangliosides (Fig. 2) nor the 
CNS gangliosides. 
Peptide Mapping to Demonstrate  that BRIC37  and IgM from 
the Serum of Patient M  Probably  Bind to Different Determi- 
nants:  The method used is a variation of a method described by Cleveland 
et al. (21). In short, a piece of human white matter was homogenized, lyophi- 
lized,  and delipidated  by three exposures to  chloroform:methanol (2:1,  by 
volume). Subsequently the material was solubilized in  I% SDS-0.125  M Tris 
HC1 at pH 6.8 and then boiled to inhibit endogenous enzymes. The following 
enzymes were  used for  peptide  mapping: (a)  trypsin;  (b)  protease  18;  (c) 
chymotrypsin; and (d) fiein (all  from Sigma Chemical Co., St.  Louis, MO). 
The digestions were carried out at 37°C and various ratios of enzyme to white 
matter were used. The reactions were stopped by adding SDS and 2-mereap- 
toethanol and by boiling.  The reaction products were separated by SDS poly- 
acrylamide (10%)  slab gel electrophoresis using the system of Laemmli (22) 
and then transferred onto nitrocellulose.  The nitrocellulose was then stained 
FIGURE 2  The figure shows strips of 
aluminum-backed  TLC  plates  con- 
taining gangliosides from human pe- 
ripheral  nerve.  The  strips  were 
stained  with  (1)  BRIC37; (2)  control 
rat mab; (3) IgM from the serum  of 
patient M;  and  (4)  with  IgM  from 
control serum.  IgM from the serum 
of patient M  binds  to a ganglioside 
that corresponds  to the description 
of Ilyas et al. (20). The other antibod- 
ies bind to nothing in the ganglioside 
preparation. 
FIGURE  1  Binding of BRIC37  and IgM from patient's serum to MAG 
on Western  blots.  Western  blots of isolated human MAG (A) and 
of homogenates  of adult human spinal cord (B) were stained using: 
(I) a control rat mab; (2) BRIC37;  (3) serum from patient M; and (4) 
a control human serum. Both BRIC37  and IgM from patient M bind 
to isolated MAG (long arrow) and dMAG (short arrow), which is a 
breakdown product of MAG. On the spinal cord blots both sera 
identified MAG and dMAG and no other proteins. 
/V~ARTON AND  STEFANSSON  Myelin-associated  Glycoprotein  1643 either with BRIC37 or IgM from the serum of patient M (see under Electropho- 
resis and  Immunoblotting).  Fig.  3  contains  the  results  from one  of these 
experiments  and  shows  that  there  are  substantial  differences  between  the 
fragments  recognized by BRIC37 on one hand and IgM from the serum of 
patient M on the other. 
Tissue Samples and Antigens:  Fresh brains and spinal cords were 
obtained at autopsy from human fetuses at 31 and 37 wk of gestation and from 
postnatal  humans at 7 mo and 30 y of age. Tissue was sampled from thoracic 
spinal cord, cerebellum, and frontal lobe. The tissue was either homogenized 
and solubilized directly or homogenized, lyophilized, and delipidated by three 
exposures to chloroform/methanol 2:1 (vol/vol), and subsequently solubilized. 
There were no differences between the results obtained by these two methods. 
Isolated human MAG was a generous gift from Dr. R. H. Quarles, (National 
Institutes of Health). Samples were solubilized in a solution containing  5.7 M 
urea, 1% wt/vol SDS, and 1% vol/vol 2-mercaptoethanol.  Solubilized samples 
were heated at 100*C for 3 min. 
Electrophoresis and  Immunoblotting:  The  solubilized  tissue 
samples and isolated MAG were separated with SDS polyacrylamide (5.6%) gel 
electrophoresis using the system of Fairbanks et al. (23). The gels were either 
stained with Coomassie Blue (23), or unstained gels were overlaid with nitro- 
cellulose sheets and the protein  bands were transferred  electrically onto the 
nitrocellulose by use of a Bio-Rad Transblot  TM cell (Bio-Rad Laboratories, 
Richmond,  CA) at 60 V for 3 h in 20 mM Tris HC1 buffer at pH 7.5 with 20% 
methanol.  The nitrocellulose sheets were cut into  strips, and the strips were 
placed individually into capped test tubes. The protein binding capacity of the 
nitrocellulose was saturated by overnight incubation  with 5% BSA in 0.145 M 
NaC1-0.05 M Tris HC1 buffer at pH 7.6 at room temperature.  This was followed 
by a 20-min equilibration  with 0.145 M NaC1-0.05 M Tris-HCl buffer at pH 
7.6 containing 0.05% vol/vol  Nonidet  P-40 (Particle Data Laboratories, Elm- 
hurst, IL), and 5% vol/vol  normal goat serum. This medium was used for all 
subsequent washings and for diluting all antibodies and sera used in the staining 
procedure. The strips were next incubated  for 1 h with BRIC37, HNK~, one of 
the control  mabs, serum from patient  M diluted  1:200, or one of the control 
sera diluted  1:200. Subsequently the strips were washed three times for 15 min. 
This was followed by a l-h incubation with peroxidase-labeled rabbit antibodies 
against rat immunoglobulins,  mouse immunoglobulins,  or human lgM (Dako 
Corp., Santa Barbara, CA). Again the strips were washed three times. Location 
of peroxidase activity was revealed by placing the strips in 0.145 M NaC1-0.05 
M-Tris-HC1 buffer at pH 7.6 containing 0.01% vol/vol H202 and 0.5% wt/vol 
diaminobenzidine  tetrahydrochloride. 
FIGURE  3  Peptide mapping of the proteins (MAG and dMAG) in 
adult human white matter that react with BRIC37 and IgM from the 
serum of patient M. A and B are nitrocellulose sheets that contain 
electrophoresed proteins from  (1)  undigested white  matter;  (2) 
trypsin digested WM; (3) protease 1  8 digested WM; (4) chymotryp- 
sin digested white matter; and (5)  ficin digested white matter. A 
was stained with BRIC37 and B was stained with IgM from the serum 
of patient M. 
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Immunohistochemical Staining with BRIC37 and IgM from 
the Serum of Patient M:  6-um  sections  of formalin-fixed  paraffin 
embedded blocks from the same central nervous system material used for the 
immunoblots were stained with BRIC37 using both the peroxidase antiperoxi- 
dase method of Sternberger (24) and a biotin avidin peroxidase technique (25). 
Adjacent sections were stained  with patient  M's serum using a biotin  avidin 
peroxidase technique.  Rat  peroxidase  antiperoxidase  complex  was obtained 
from Sternberger-Meyer  Immunoccytochemicals (Jarettesville,  MD)  and  re- 
agents for the biotin  avidin  peroxidase procedure,  from Vector Laboratories, 
Inc. (Burlingame, CA). 
RESULTS 
The results of immunohistochemical staining obtained with 
BRIC37 are identical to the results obtained through the use 
of serum from patient M  and correspond to the previously 
described distribution of MAG (4). On immunoblots BRIC37, 
IgM  from patient  M  (Fig.  1),  and  HNK~  (data not shown) 
bind  to  isolated  human  MAG  and  on  immunoblots  from 
homogenates of  adult human spinal cord they bind exclusively 
to MAG and dMAG. 
Immunoblots 
When the three anti-MAG antibodies are applied to human 
CNS  tissue  at  various  stages  of development,  a  surprising 
variety of proteins are found to react with the antibodies. On 
blots of the frontal lobe homogenate from a 31-wk-old fetus, 
the  antibodies  bind  to  a  group  of at  least  two  very  high 
molecular weight proteins,  the  smaller one with  molecular 
weight of ~250,000  (Fig.  4a).  In the 37-wk-old frontal lobe, 
in addition to the higher molecular weight proteins recognized 
in the 3 l-wk-old, two new major proteins appear, one with a 
molecular weight of ~200,000  and the other ~ 130,000.  By 7 
mo postnatally the 200- and the 130-kd proteins have become 
more  prominent.  In  the  adult  frontal  lobe  the  antibodies 
recognize only 100- (MAG) and 90-kd (dMAG) proteins. 
In the homogenate of cerebellum from the 31-wk-old fetus, 
the antibodies elicit a banding pattern quite similar to the one 
in frontal lobe of the same age (Fig. 4 b), but the shift towards 
the low molecular weight occurs at an earlier age in cerebellum 
than in frontal lobe. 
In the spinal cord homogenates at 31 wk, in addition to the 
very  high  molecular  weight  proteins  that  were  the  only 
"MAG-related" proteins detected in the frontal lobe at 31  wk 
(Fig. 4c), the 100- and 90-kd proteins as well as the interme- 
diate 200-kd protein have appeared. At 7 mo postnatally, the 
group of heaviest bands has disappeared from the spinal cord 
(Fig. 4c). In the adult spinal cord the antibodies bind to the 
same two bands as they do in the adult frontal lobe (100- and 
90-kd)  which  co-migrate  with  isolated  human  MAG  and 
dMAG (4 c). 
Examination of the results of staining the three CNS regions 
from the 37-wk-old fetus demonstrates that the shift towards 
the lower molecular weights occurs first in the areas that are 
myelinated earliest;  it is seen first in the spinal cord, then in 
the cerebellum, and finally in the frontal lobe (Fig. 4 d). 
On  the  immunoblots  there  are  some  differences  in  the 
relative intensities of the bands elicited by BRIC37 as opposed 
to the IgM  from the serum of patient M.  This is especially 
evident in Fig.  4 d. Antibodies from the serum of patient M 
detect the  heaviest MAG-related  protein more readily than 
does BRIC3v while BRIC37 detects the 200-kd antigen more 
readily than do the antibodies from patient M. This variation 
probably reflects that the two antibodies differ in their epitope FIGURE 4  Binding of BRIC3z and IgM from the serum of patient M to high  molecular weight components of developing CNS 
tissue. Homogenates of frontal lobe (A), cerebellum (B), and spinal cord (C) were prepared from humans aged 31-wk gestation, 
37-wk gestation,  7  mo  postnatally and  30  y  of age. The samples were run  on  SDS  polyacrylamide gels and  transferred  to 
nitrocellulose. In D, samples of each of the three CNS regions from the 37-wk fetus are compared. The strips were stained using 
(1) control rat mab; (2) BRICk7;  (3) serum from patient M; and (4) control human serum followed by peroxidase-conjugated  anti- 
rat immunoglobulin (1 and 2) or anti-human IgM (3 and 4). Western  blots of isolated MAG are included at the right end of each 
panel to show the mobility of isolated adult MAG (long arrow) and dMAG (short arrows). In each tissue (A-C) there is a decrease 
with age  in  the apparent molecular weight of proteins recognized by the anti-MAG antibodies. In the 37-wk  fetus  (D)  this 
decrease is most pronounced in the spinal cord and least in the frontal lobe which is in keeping with the stage of myelination in 
these areas. In D it can be seen that the IgM from patient M is more sensitive than BRIC37  in detecting the >250 kd MAG-related 
proteins while the rat antibody is more sensitive for the 200-kd protein. The heavy chain of IgM migrates on these gels just ahead 
of dMAG. Endogenous IgM was detected in some of the tissue blots treated with peroxidase-conjugated  anti-human IgM and is 
indicated with a dot. It is also noteworthy that the ratio of MAG to dMAG varies from one sample to another. In most of the fetal 
tissues dMAG predominates. 
specificity.  HNK~  binds  to  the  same  proteins  in  the  fetal 
material as do BRIC37 and IgM from the serum of patient M. 
The relative intensity of the  bands stained by HNK,, is in 
between the patterns of BRIC37 and IgM from the serum of 
patient M  (data not shown).  Fig.  5 shows Coomassie Blue- 
stained SDS polyacrylamide gels  of the tissue samples used 
on the immunoblots. 
Immunohistochemistry 
Both BRIC37 and IgM from patient M's serum stain only 
the periaxonal portion of myelin sheaths in adult CNS but 
just prior to and during myelination they also stain oligoden- 
drocytic cytoplasm. This immunohistochemical pattern is the 
same as that obtained by use of polyclonal antiserum against 
MAG (4). However, thus far we have not been able to correlate 
the immunohistochemical staining of myelin sheaths versus 
oligodendrocytic cytoplasm with  the  molecular weight pat- 
terns on the immunoblots. 
DISCUSSION 
We have demonstrated that anti-MAG antibodies react with 
proteins in  homogenates of CNS tissue from young human 
fetuses that  have  molecular  weights  much  larger than  the 
MAG found in  adult  myelin.  During myelination the  high 
molecular  weight  proteins  disappear  and  lower  molecular 
weight proteins reactive with the  anti-MAG antibodies ap- 
pear.  When  myelination is completed,  the  antibodies bind 
only to proteins with  molecular weights identical to  MAG 
and dMAG  (Fig.  4).  We have also shown that this change 
from high to low molecular weights occurs first in the spinal 
cord where myelination proceeds faster than  in  cerebellum 
and cerebrum and latest in the cerebrum where myelination 
is completed after the other two regions (26) (Fig. 4). We have 
therefore shown both by looking at the CNS from individuals 
at  various stages  of development and  by looking  at  three 
regions from the CNS of each of these individuals that the 
shift from high to low molecular weights amongst proteins 
reactive with anti-MAG antibodies appears to follow myeli- 
nation. 
It is  possible  that  MAG  and  the  high  molecular weight 
proteins reactive with the anti-MAG antibodies are unrelated 
except for that  they  react with  the  antibodies  used  in  this 
study.  However this has to be considered improbable since 
BRIC37 and  the  mabs from patient  M's  serum  react with 
different epitopes on  MAG and  the  high  molecular weight 
proteins  and  MAG  are  developmentally reciprocal  (MAG 
appears when the high molecular weight proteins disappear). 
HNK~  may  react  with  a  third  determinant  since  neither 
BRIC37 nor the patient's IgM react with human natural killer 
cells but HNK~ does. The failure to stain natural killer cells 
with the IgM paraprotein and BRIC37 may however be due 
to low avidity of these antibodies rather than absence of the 
complementary antigenic determinants from the lymphocytes 
and therefore does not prove that HNK~ reacts with an epitope 
different from BRIC37 or the IgM paraprotein. 
MARTON AND  STEFANSSON  Myelin-associatedGlycoprotein  1645 FIGURE 5 Coomassie Blue-stained SDS polyacrylamide gels of the 
tissue homogenates used in Fig. 4 show the total protein composi- 
tion of the samples. Frontal lobe (A); cerebellum (B); and spinal 
cord (C): (1) 31-wk gestation; (2) 37-wk gestation; (3) 7-too postna- 
tally; and (4) 30 y of age. 
This developmental change in molecular weights of"MAG- 
related proteins" is reminiscent of developmental changes 
that have been reported to occur in the molecular weights of 
myelin basic protein (MBP) or MBP-related proteins in mouse 
brain (27, 28). On immunoblots of homogenates of cerebrum 
from newborn mice, antibodies specific for MBP react only 
with a protein with a molecular weight of -34,000, but as 
myelination proceeds, the reactivity becomes gradually con- 
fined to the four main peptides of the MBP family (21.5, 18.5, 
17, and 14.0 kd). It has also been shown that the difference 
between molecular weights of proteins reactive with anti-MBP 
antibodies at various stages of development are probably not 
due to post-translational events (29). 
Currently we have no way of predicting whether the differ- 
ence between MAG and the high molecular weight proteins 
reactive with anti-MAG antibodies will be explained by dif- 
ferent genes, age-dependent differences in gene expression, 
difference in translatability ofmRNA, post-translational mod- 
ification, or some other mechanism. Irrespective of how the 
differences between the "mature MAG" and the high molec- 
ular weight proteins reactive with the anti-MAG antibodies 
will be explained, the transient existence of these high molec- 
ular weight proteins during development may provide a way 
to monitor some of the events on the basis of which myeli- 
nation and remyelination occur. 
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